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Radioimmunoassay of Serum Estrogen
Nai-Siang Jiang, Robert J. Ryan, and A. Albert Radioimmunoassay of serum estrogen (sum of estrone and estradiol-17f3) in 0.5 ml of human serum is described.
After dilution of the serum, the estrogens are adsorbed on a Sephadex G-15 column in the presence of dilute HC1 and then eluted with benzene. After evaporation of the benzene eluate, the estrogens are dissolved in bovine serum albumin (5 g/. liter solution, at pH 8.0). An aliquot of this solution is used for the assay. Serum estrogen concentrations (mean ± SD) were 69 ± 23 pg/mI in 105 normal men and 199 ± 146 pg/mI in 26 fertile women. In 109 postmenopausal women, estrogen was undetectable in seven sera, but in the remaining 102 it was 52 ± 30 pg/mt of serum. The nature and amounts of estrogens in human body fluids have recently been reviewed (1) . Estrogens in serum or plasma have been determined by gas chromatographic and double-isotope derivative methods (2) (3) (4) , which require relatively large amounts of plasma or serum, are tedious to perform, and restricted in the number of samples that can be assayed in one run. Greater convenience (smaller volumes of sample, greater number of tests carried out per run, less tedium in performance) was achieved by use of radioimmunoassay (5-7), competitive binding assay (8) (9) (10) , and receptor binding assay (11, 30, 31) . However, preliminary extraction, purification, and separation of the estrogens are still required, so that the amounts of estrone (E1) 1 To achieve the distinctive features of a clinical assay, we approached the problem of serum estrogen determination from a different route. Under most ordinary circumstances the diagnostic value of estrogen assay is reportedly the same, whether one, two, or three of the three major estrogens are measured (13) . If this indeed is the case, then meaningful clinical information can be obtained by a determination of collective plasma estrogens, thus avoiding the necessity of extensively purifying and separating them into two or three components.
This we did by preparing an extract of serum containing only E1 and E2, which can be done very quickly and quantitatively, and using radioimmunoassay to measure the sum of these two estrogens.
Materials and Methods

General
procedures.
All chemicals were reagent grade. Estrone, estradiol-17i9, and estriol were obtained from Sigma Chemical Co., St. Louis, Mo. 63178, and further purified by recrystallization.
The purity of the final product was checked by paper chromatography.
All other steroids were the best grade available from commercial sources and were used without further purification.
Labeled E2 (6,7-3H estradiol-17f3 or TE2) with a specific activity of 42 Ci/ mmole was obtained from New England Nuclear, Boston, Mass. 02118. The E2 antiserum was produced in our laboratory by injecting rabbits with estradiol-17 succinyl bovine serum albumin (E2-BSA).2 The scheme for immunization was similar to that reported previously (12) . Six rabbits were injected subcutaneously with 1 mg of E2-BSA per week. During the first two weeks, antigen was given in 1 ml of complete Freund's adjuvant. Subsequent injections were given in 1 ml of NaCl solution (9 g/liter). The animals 2 The antigen E2-BSA was a gift from the National Cancer Institute.
were bled six weeks after the first injection and every two weeks thereafter. The serum was separated from the clot, sodium azide added in a final concentration of 1 g/liter, and stored in the deep freeze until used.
Purification of solvents.
Benzene was purified by repeated washing with tenth volumes of concentrated H2S04 until the acid layer was colorless. The organic layer was then washed with a tenth volume of 0.1 molar NaOH and with several portions of water until the aqueous phase was pH 5.5, then dehydrated over anhydrous Na2SO4 and distilled twice. E2-antiserum (0,5 ml of a 500-fold dilution) was incubated with 40,000 cpm of TE2 in a final volume of 5 ml of Tris buffer (0.05 mol/liter, pH 8.0). Simultaneously, a control tube was prepared under identical conditions except 0.5 ml of normal rabbit serum (500-fold dilution) was used instead of E2 antiserum.
The mixtures were incubated at room temperature overnight. After incubation, the following experiments were performed on the mixtures: a. Sephadex G-75 column chromatography. One milliliter of each of the incubation mixtures was added to the top of a Sephadex G-75 column (1 X 7.5 cm). After the 1 ml solution percolated through, the column was eluted with 0.05 molar Tris buffer, pH 8.0. The column was operated at 4#{176}C. Thirty-six fractions (1 ml each) were collected, and radioactivity was counted.
b. Treatment with Dowex-l-Cl resin. One milliliter of the incubation mixture was treated with 20 mg of Dowex-1-Cl (Ag 1-x2, Bio-Rad, 100-200 mesh) for #{149} 30 mm in an ice-water bath, with occasional mixing, then centrifuged at 1,000.X g at 4#{176}C for 5 mm and the supernatant solution was subjected to Sephadex G-75 column chromatography as described above. The radioactivity of the fractions was measured.
c. Treatment
with DS charcoal. One milliliter of the incubation mixture was added to 0.25 ml of DS charcoal (containing 12.5 mg of Norit A) and mixed with a vortex-type mixer, incubated in an ice-water bath for 30 mm, and centrifuged at 1,000 x g at 4#{176}C. The supernatant solution was chromatographed on Sephadex G-75 column and the radioactivity of the fractions was measured as described above.
Second-stage antibody precipitation (14)
. To 1 ml of the incubation mixture was added 0.1 ml of normal rabbit serum-a threefold dilution in 0.05 molar Tris buffer, pH 8.0-and 0.1 ml of goat antiserum against normal rabbit serum. The mixture was vortex-mixed and incubated at 4#{176}C overnight. At the end of the incubation the mixture was centrifuged at 10,000 x g at 4#{176}C for 20 mm. The supernatant solution was decanted, the precipitate was redissolved in 1 ml of the Tris buffer, and the radioactivity was measured.
Specificity study. We studied the specificity of the E2-antiserum by incubating, in duplicate tubes, 0.4 ml of E2-antiserum, 210-fold dilution; 10,000 cpm TE2; and various amounts of the different steroids tested in a total assay volume of 1.2 ml, using the Tris buffer to adjust all tubes to the same volume. Two tubes without steroid served as 100% controls and two tubes without E2-antiserum served as blank controls. The tubes were incubated at room temperature overnight; each tube was then treated with 0.25 ml of DS charcoal, as described above, to remove free TE2. The radioactivity of 1 ml of the supernatant solution was measured. The average counts per minute of the duplicates, with blank subtracted, was expressed as a percentage of that of the 100% tube. A displacement curve was constructed for each steroid, with logarithm of the steroid added (in picograms)
as abscissa and the percent TE2 bound as ordinate.
Purification of E1 and E2 from human serum. The procedure developed by Van Baelen et al. (16) for purification of estrogens from urine was modified for processing serum samples. Sephadex G-15, 800 mg, was packed in a column (1 cm i.d.) having a porous glass plate at the bottom. The whole column was immersed in water overnight, or longer, in a 1.5 x 15 cm test tube. The column was washed with 10 ml of water immediately before use. The serum to be assayed was diluted eightfold by mixing 1.1 ml of serum, 4.7 ml of water, and 3.0 ml of 0.16 molar HC1. Four milliliters of the diluted serum was transferred to the top of the Sephadex G-15 column. This procedure was done in duplicate for each sample. For column blanks, two columns, to each of which 4 ml of dilute acid was applied instead of the serum sample, were developed for each assay. After the 4-ml sample had percolated through, the column was washed with 7.5 ml of water to remove serum proteins and other interfering substances, and residual water on the column was removed by briefly applied suction. The estrogens, still retained on the column, were eluted with 10 ml of either ethyl acetate or benzene, which was forced through the column by compressed air. In the final procedure, benzene was selected for the elution because it eluted only E1 and E2. The organic solvent eluate was evaporated in a 65#{176}C water bath under a gentle stream of nitrogen.
The residue was redissolved in 1 ml of BSA solution (5 g/liter of Tris buffer) by shaking on a rotary shaker for 40 mm. The resulting solution was used for assay.
Radioimmunoassay of estrogen.
The assay mixture contained 2,500 cpm of TE2 (33 pg), standard E2, or sample extract, and 0.1 ml of 210-fold diluted E2-antiserum and sufficient Tris buffer to make a total volume of 1.2 ml. Duplicate standard tubes contained 0, 10, 20, 40, 80, or 160 pg of E2, which was transferred to the tubes in a volume of 0.7 ml of the BSA-Tris solution.
Two tubes without antiserum served as blank.
The amount of benzene extract used in the assay depended on the expected E1 and E2 concentration in the sample. When the expected concentration was less than 400 pg/ml of serum, 0.7 ml of the final extract was used for the assay. When the concentration was expected to exceed 400 pg/ml serum, 0.2 ml of the extract was used. In the latter case, 0.5 ml of BSA-Tris solution was added to adjust the final incubation volume to 1.2 ml. The incubation mixture was left overnight (15 h) at room temperature. The next morning, the tubes were chilled in an ice-bath for 10 mm; then 0.25 ml of DS charcoal (containing 12.5 mg of charcoal) was added to each tube and vortex-mixed.
The mixture was set in an ice-water bath for an additional 30 mm with occasional mixing. After centrifugation at 4#{176}C and 1,000 X g for 5 mm, the supernatant fluid was poured into a liquid scintillation counting vial without disturbing the precipitate. A standard displacement curve was constructed as described above and, from the percent bound TE2 found in the tubes containing unknowns, the quantity of E1 and E2 could be read from the standard curve. The final calculation was simple: 1 ml of extract was the equivalent of 0.5 ml of original serum, so 0.7 ml of extract represents 0.35 ml of serum, and 1 ml of serum = 
Results
Separation
of bound and free estrogen. Figure 1 shows the elution patterns of free and antibody-bound TE2 from a Sephadex G-75 column. to When E1 and E2 were added to male serum and benzene was used to elute the column, recovery was good (Table 1) . Figure 4 shows the histogram of serum estrogen concentrations in normal subjects, postmenopausal women, hypogonadal patients, and children. In most of the hypogonadal patients and all of the children examined, estrogen was undetectable in serum, whereas none of the normal subjects examined had serum estrogen values of less than 30 pg/ml. Figure 5 illustrates the patterns of urinary total estrogen, serum estrogen (measured by the present method), and serum luteinizing hormone during a normal menstrual cycle. The pattern of serum estrogen parallels reported patterns of estrogen in both blood and urine during the menstrual cycle. Table 4 shows the inter-and intra-assay precision of the present method.
The radioimmunoassay of serum estrogen can be outlined as follows: 1. Apply 4 ml of dilute serum (1.1 ml of serum + 4.7 ml of water + 3.0 ml of 0.16 mol/liter HC1) to each of two Sephadex G-15 columns. Wash the columns with 7.5 ml of water, elute with 10 ml of benzene, and flush with compressed air. Evaporate the eluate at 65#{176}C under nitrogen. Dissolve the residue in 1 ml of albumin-containing (5 g/liter) buffer, pH 8.0.
2. Use 0.7 or 0.2 ml of the extract in radioimmunoassay, with concomitant standard solutions of E2, 100% tube, and blanks, in a total reaction volume of 1.2 ml of buffer. Incubate for 15 h (overnight) at room temperature.
Mix with 0.25 ml of DS charcoal, centrifuge, pour the supernatant fluid into a counting vial, and measure radioactivity.
3. From the percent counts bound of unknown, read from the standard curve the corresponding value in picograms of estrogen. If 0.7 ml of extract was used: Fig. 5 . Urinary total estrogen, serum estrogen, and serum Iuteinizing hormone during normal menstrual cycle; LH is expressed as nanograms of LER-907/ml pg estrogen x 2.86 = pg estrogen/mI serum. If 0.2 ml of extract was used: pg estrogen X 10 = pg estrogen/ ml serum.
Discussion
Some additional information obtained during the development of the present method will be given here in order that others who may wish to introduce some modifications will benefit from our failures. Although the assay is generally simple, meticulous attention to technical details is required if results are to be consistent and reproducible.
The maximum sample volume (after dilution) for the Sephadex G-15 column is 4 ml; use of larger volumes results in poor recovery.
For good recovery, the serum sample must be diluted eightfold; hence, the maximum serum volume for extraction is 0.5 ml. All the radioimmunoassays and competitive binding assays for estrogens described in the literature have been applied after chemical separation of E1 and E2. We agree with the general rule that it is best to assay a single substance whose chemical identity is known. However, lengthy extraction and chromatographic procedures are required to separate the two estrogens.
Because recoveries are generally low in these procedures, relatively large quantities of tntium-labeled hormones have to be added to the sample to correct for losses, and the extracts obtained generally give relatively high blank values. The complexity of the separation methods and the resulting difficulties imposed by separation constitute grounds for not following the general rule when the assay is performed for routine clinical purposes. In the present method, the sum of E1 and E2 is measured, because the antiserum does not differentiate significantly between them and there are the advantages that the purification steps are considerably simplified and no correction factor is needed because the recovery is consistently excellent. One technician can easily use 46 columns (23 duplicate samples) and complete the assays within one and one-half working days, exclusive of counting time. The blank value also is low in the present method. The mean ± SD for 42 column blanks (data collected over a period of several months) was 96.8 ± 4.3% of control tubes. by Nagai and Longcope (30) and Korenman et al. (11, 31) , but is somewhat lower than that reported by Baird and Guevara (4). For postmenopausal women, our value agrees well with that of Korenman et al.
(11, 31) but is higher than that reported by Nagai and
Longcope (30) . The difference nay be attributed to the fact that the subjects studied by Nagai and Longcope were considerably older.
Although urinary total estrogen (E1, E2, and E3) determination (18, 19) has been used as an index of gonadal function for some time, the present paper represents the first attempt to apply the same principle to serum. We believe that the combined E1 and E2 value can be used as a valid index of gonadal function because these two estrogens are interconvertible (20) (21) (22) in the body, both have biological activity, and are both secreted by the gonads (23-25) . The cyiticism could be raised that the combined serum E1 and E2 value may not be a valid index of gonadal function since a considerable amount of E1 in the blood derives from extra-gonadal sources (26) (27) (28) . However, the extra-gonadal contribution of E1 is relatively constant.
The major source of extra-gonadal E1 is the peripheral conversion of M-androstenedione to E1. MacDonald and his associates (27) have shown that the fraction of radioactivity appearing in the urinary metabolites of estrogens after administration of radioactive i.4-androstenedione is similar in normal and castrated individuals.
Longcope (29) found that there is little if any difference in the rate at which androstenedione is converted to E1 by fertile and postmenopausal women. Longcope et al. (24) have also shown that the amount of androstenedione converted to E1 in men and women varied from 30-50 zg/day. Therefore, a relatively constant concentration of estrogen represents the extra-gonadal contribution of E1, whereas a fluctuating proportion represents the gonadal contribution.
The former probably is below detectability by the present assay, because most hypogonadal individuals and some postmenopausal women showed undetectable amounts (see Figure 4 ). All castrated individuals that we have examined to date yield undetectable values. The part that is measurable in the present assay probably represents estrogens secreted by the gonads. We believe that, owing to its simplicity and speed, the present method will be useful as a routine diagnostic procedure because the estrogen values are in general accord with the clinical condition of the individuals, and second, the serum estrogen values in one complete menstrual cycle showed a typical biphasic pattern related to the surge in luteinizing hormone, a pattern rather fully documented by a variety of chemical methods for assay of estrogen.
Further evidence that the combined measurement of E1 and E2 serves as an index to estrogen production by the gonad can be derived from in Table 5 was made for men, fertile women, and postmenopausal women. These three indices of estrogen production were arranged in Table 6 in ascending order from left to right. E1 is about the same for postmenopausal women and men and about twice this amount in fertile women. E2 is lowest in postmenopausal women, twice this value in men, and 10-fold this postmenopausal concentration in fertile women. The sum of E1 and E2 is about 42% greater in men than in postmenopausal women, and four times greater in fertile women. Thus, while E2 measurements may show a more active response as a function of gonadal activity, it is true, as earlier work on urinary estrogens showed, that the sum of E7 and E2 likewise reflect gonadal activity. 
